兄弟们，最近A股市场有点不平静啊。华银电力突然宣布上半年净利润暴增4423%，直接把股价拉了个76%的月涨幅，连带着整个预增板块都跟着火了一 把。这可不是个例，截至7月10号，已经有487家公司发了中报预告，其中126家预增超过100%，连天赐材料这种龙头都单月涨了45%。作为在财经圈混了20 年的老江湖，今天咱们就来聊聊这波预增行情，到底该怎么抓住机会，又该避开哪些坑。 今年预增股主要扎堆在三个方向：电子行业受益于AI爆发，工业富联的AI服务器营收涨了60%，芯动联科的MEMS传感器在军工订单里卖爆了；化工行业因 为产品涨价，先达股份的除草剂烯草酮涨到16万一吨，直接让利润翻了28倍；医药生物则是多肽药物需求激增，翰宇药业的利拉鲁肽注射液拿到FDA认证， 净利润暴增16倍。这三个方向既有政策支持，又有实实在在的业绩，是中长线布局的好选择。 风险提示：别被表面数据忽悠了 这里得给兄弟们提个醒，不是所有预增股都能买。比如渝开发虽然预增784%，但主要是靠卖子公司股权赚了2.4亿，扣非净利润可能还不如主业稳定的公 司。另外，像华银电力这种靠短期电力需求激增的公司，一旦天气转凉或者产能过剩，业绩可能马上变脸。还有些 ...

关于对通化东宝药业股份有限公司 德皓函字202500000105 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于对通化东宝药业股份有限公司 德皓函字2025 00000105号 上海证券交易所上市公司管理一部： 由通化东宝药业股份有限公司（以下简称"通化东宝"或"公 司"）转来的《关于通化东宝药业股份有限公司 2024 年年度报告的 信息披露监管问询函》 （上证公函【2025】0898 号） （以下简称" 《问 询函》"）奉悉，本所作为通化东宝 2024 年度财务报表审计的会计 师事务所，现就《问询函》中需要年审会计师发表意见的有关事项 核查说明如下： 进行两次更正：公司原预计归母净利润 4,053 万元，2 月 26 日进行 第一次更正，将预计归母净利润调整为 1,164 万元，主要系侵害商 标权 诉讼终审判决公司赔付 6,131 万，较此前预计的 3,000 万元差 异较大； 将预计归母净利 ...

Core Insights - The 2025 semi-annual performance forecasts of listed companies have been disclosed, with 152 A-share companies reporting, of which 101 expect profit increases, 10 expect to turn losses into profits, and 15 expect profit decreases, indicating a positive trend in overall performance [1][4]. Group 1: Performance Highlights - Huayin Power leads with an expected net profit increase of 4423%, driven by high temperatures and increased electricity demand, projecting a net profit of 180 to 220 million yuan [4][5]. - Xinda Co. follows with a projected net profit increase of 2834.73%, attributed to rising prices of its core herbicide product, with a current market price of 120,000 to 160,000 yuan per ton [5]. - Shen Shen Fang A has reversed its losses with an expected net profit of 85 to 120 million yuan, a significant increase due to a recovery in the Greater Bay Area's new housing market [5][6]. Group 2: Industry Performance - The electronics, chemical, and pharmaceutical sectors are experiencing high growth, with 111 companies reporting profit increases, particularly in the electronics sector with 15 companies showing positive forecasts [8][9]. - Industrial Fulian expects a net profit of 11.96 to 12.16 billion yuan, benefiting from a 60% increase in AI server revenue [9][10]. - The chemical sector is also thriving, with companies like Xinhong Cheng expecting a net profit of 3.3 to 3.75 billion yuan, driven by increased sales and prices of core products [12]. Group 3: Pharmaceutical Sector Recovery - Several pharmaceutical companies are seeing a resurgence, with Hanyu Pharmaceutical projecting a net profit increase of 1470.82% to 1663.89% due to the approval of its weight-loss drug in the U.S. [14]. - Shengnuo Bio expects a net profit of 77.02 to 94.14 million yuan, driven by strong sales in the peptide raw material business [14]. - Shanghai Pharmaceuticals anticipates a net profit of 4.45 billion yuan, a 52% increase from the previous year, due to acquisitions and consolidation [14].

Core Insights - A total of 152 A-share companies have released their performance forecasts for the first half of 2025, with 101 companies expecting profit increases, 10 companies turning losses into profits, and 15 companies predicting profit decreases [1] - The most significant profit increase is expected from Huayin Power, with a projected net profit surge of 4423% [2][3] - The semiconductor and server sectors are benefiting from the rapid development of the artificial intelligence industry, leading to substantial growth in earnings for electronic companies [1][6] Company Performance Highlights - Huayin Power anticipates a net profit of 180 million to 220 million yuan, an increase of 175 million to 215 million yuan compared to the previous year, representing a growth rate of 3600.7% to 4423.07% [2] - Xianda Co. expects a net profit of 130 million to 150 million yuan, a significant increase of 125 million to 145 million yuan from approximately 532.12 thousand yuan last year, with a year-on-year growth rate of 2443.43% to 2834.73% [3] - Deep Shenzhen A is projected to achieve a net profit of 85 million to 120 million yuan, marking a year-on-year increase of 1411.70% to 2034.17% after two years of losses [3] Industry Trends - The electronic, chemical, and pharmaceutical sectors are experiencing high levels of profitability, with 111 companies reporting profit increases or turning losses into profits [6] - Industrial Fulian expects a net profit of 11.958 billion to 12.158 billion yuan, driven by a more than 60% year-on-year increase in AI server revenue [7] - The chemical sector is seeing profit growth due to rising demand and prices for core products, with companies like New Hope and Juhua Co. reporting significant increases in net profits [9] Pharmaceutical Sector Recovery - Hanyu Pharmaceutical is projected to achieve a net profit of 142 million to 162 million yuan, a year-on-year increase of 1470.82% to 1663.89% after receiving FDA approval for its weight-loss drug [10] - Shengnuo Bio expects a net profit of 77.02 million to 94.14 million yuan, reflecting a growth of 253.54% to 332.1% due to strong performance in the peptide raw material business [10] - Shanghai Pharmaceuticals anticipates a net profit of 4.45 billion yuan, a 52% increase from the previous year, attributed to acquisitions and consolidation adjustments [10]

此外，就在7月1日，翰宇药业发布今年半年利润的业绩预告称：2025年上半年，公司预计实现归母净利 润1.42亿-1.62亿元，同比增幅高达1470%-1664%；扣非净利润1.22亿元-1.42亿元，同比增长 304.27%-337.76%。值得注意的是，翰宇药业能做到这一步实在不容易，公司曾陷于扣非净利润亏损长 达7年之久，这还是首次实现扭亏为盈。翰宇药业将最大功臣归于其"减重神药"利拉鲁肽注射液仿制药 的出海成功以及原料药的国际收入和成本控制等。去年12月，其仿制的利拉鲁肽注射液在美国上市，并 和美国合作伙伴Hikma采取"低出货价+高利润分成的BD"模式。 外资药企进军新赛道 与此同时，外资药企也并没有"坐等"后来者赶超，而是在不断开拓进军新赛道。就在2025年6月30日， 礼来宣布穆峰达®（替尔泊肽注射液）获得中国国家药品监督管理局批准，成为首个且目前唯一用于治 疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞 性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。 据悉，除了改善睡眠呼吸暂停症状外，接受替尔泊肽治疗的成人患者 ...

华夏时报记者黄敏璇胡梦然深圳报道 6月最后一天，深圳创新药企翰宇药业（300199）(300199.SZ)发布业绩预告，公司上半年预计实现归属净利润1.42 亿元至1.62亿元，同比大增1470.82%至1663.89%；扣非净利润1.22亿元至1.42亿元，同比增长304.27%至 337.76%，同比实现扭亏为盈。而在此之前，翰宇药业扣非净利润已连亏7年。 此番业绩大涨与翰宇药业一款仿制药在美上市有关。2024年12月，翰宇药业生产的利拉鲁肽注射液获美国食品药 品监督管理局(FDA)批准，成为美国首款利拉鲁肽仿制药，公司还与Hikma签署累计3.38亿元的合同开拓美国市 场。 不过，就在翰宇药业拿下美国首款利拉鲁肽仿制药的4个月后，今年4月，国内另一药企健友股份也公告，公司旗 下利拉鲁肽注射液获FDA批准，即将在美上市销售。这意味着，翰宇药业很快将面临与健友股份、原研药企业诺 和诺德在美正面竞争的局面。 翰宇药业方面7月2日向《华夏时报》记者表示："公司与Hikma制剂商业化合作在有序顺利推进，采取低出货价 +高利润分成的BD(Business Development)国际合作模式。"据公司高管在今年5月 ...

长江商报消息 ●长江商报记者 潘瑞冬 多肽类药物研发企业翰宇药业（300199.SZ）业绩强劲增长。 长江商报记者注意到，2024年12月23日，翰宇药业向美国食品药品监督管理局申报的利拉鲁肽注射液获 得批准证书并实现销售。根据翰宇药业董秘回答投资者内容，至2025年1月，利拉鲁肽注射液已向美国 合作方完成近140万支发货。 近年来，翰宇药业海外收入猛增。数据显示，2021年和2022年，公司的国外营业收入分别为4693.92万 元、7925.94万元，营收占比仅为6.38%、11.25%。 到2023年和2024年，翰宇药业的国外营业收入已涨至1.12亿元、3.25亿元，营收占比也提升至26.01%、 55.1%。 可以看到，翰宇药业已经从4年前的国内营收为主，转为国内外营收并重的药企，国外营收比例已经暂 时超过国内。 6月30日晚间，翰宇药业发布2025年半年度业绩预告，公司业绩延续了一季度强劲增长态势。上半年公 司预计实现归母净利润1.42亿元至1.62亿元，扣非净利润为1.22亿元至1.42亿元，均同比扭亏为盈。 长江商报记者注意到，盈利能力大幅增长，主要是受益于公司减重药物利拉鲁肽在国外销售取得突破 ...

Core Viewpoint - The A-share companies have accelerated the disclosure of mid-term performance forecasts, with 8 companies announcing their forecasts this week, indicating a positive trend in profitability for most companies [1][4]. Group 1: Company Performance Forecasts - Among the 8 companies that disclosed their mid-term forecasts, 7 expect to report profits while 1 anticipates a loss [1]. - Han Yu Pharmaceutical is projected to achieve a net profit of 142 million to 162 million yuan, representing a year-on-year growth of 1470.82% to 1663.89%, the highest growth rate among the companies [1][3]. - Xinhecheng forecasts a net profit of 330 million to 375 million yuan, with a year-on-year increase of 50% to 70% [2][3]. - Guomai Technology expects a net profit of 12.5 million to 15.6 million yuan, with a year-on-year growth of 60.52% to 100.33% [2]. - Weichai Heavy Machine anticipates a net profit of 13.18 million to 15.06 million yuan, with a year-on-year increase of 40% to 60% [2]. - The only company forecasting a loss is Shida Shenghua, expecting a loss of 52 million to 60 million yuan, a decline of 236.64% to 257.66% year-on-year [2][3]. Group 2: Industry Insights - Han Yu Pharmaceutical's revenue is primarily driven by international business, benefiting from global market demand, approval of its product by the FDA, and effective cost control [3]. - Xinhecheng, a leader in the vitamin industry, reported growth in sales volume and prices of its main products in the nutrition segment, contributing to its improved performance [3]. - The overall trend in the A-share market shows that out of 29 companies that have released mid-term forecasts, 27 expect profits and 2 anticipate losses, with 23 companies projecting year-on-year profit growth [4].

其 他 报 告 2025年07月02日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3458 | 0.39 | 1.91 | | 深证成份指数 | 10476 | 0.11 | 3.73 | | 沪深300指数 | 3943 | 0.17 | 1.95 | | 创业板指数 | 2148 | -0.24 | 5.69 | | 上证国债指数 | 226 | 0.02 | 0.02 | | 上证基金指数 | 6939 | -0.01 | 0.37 | 资料来源:同花顺iFinD | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 24072 | -0.87 | 3.20 | | 中国香港国企指数 | 8678 | -0.96 | 2.76 | | 中国台湾加权指数 | 22554 | 1.34 | 2.42 | | 道琼斯指数 | 44095 | 0.63 | 3.82 | | ...

连续7年扣非净利润亏损的翰宇药业（300199.SZ），终在2025年上半年迎来转机。 6月30日晚，翰宇药业发布2025年半年度业绩预告，预计净利润1.42亿-1.62亿元，同比扭亏（去年同期亏损1035.88万元）。公司将此归因于利拉鲁肽注射液 在美国获批上市并放量销售、原料药出口增长及成本控制。 利拉鲁肽这款用于治疗2型糖尿病的GLP-1类药物，因兼具减重效果成为翰宇药业翻盘的关键。2024年12月，其利拉鲁肽注射液获FDA批准，随即在2025年1 月完成近140万支发货。截至去年年底，公司已收到美国合作方Hikma累计4639.63万美元订单。 但这款"救命药"的国内故事已画上句号。2023年6月，翰宇药业主动撤回利拉鲁肽国内上市申请，并于同年11月终止项目，全额计提减值5298.82万元。去 年，翰宇药业又将司美格鲁肽的国内权益转让给三生制药（01530.HK）旗下三生蔓迪。两个选择背后，是公司对国内GLP-1市场未来价格战的预判，同时也 吹响公司全力押注海外市场的号角。 翻盘全靠利拉鲁肽 公开资料显示，翰宇药业成立于2003年，2011年登陆深交所创业板，主营多肽制剂及原料药，主要产品包括多肽原料 ...